Faeth Therapeutics (FTH) Free Cash Flow (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Free Cash Flow came in at -$10.7 million in Q1 2026, down 51.38% YoY from -$22.1 million in Q1 2025, and down 177.92% on a QoQ basis from -$3.9 million in Q4 2025.
Faeth Therapeutics (FTH) Free Cash Flow (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Free Cash Flow data on file, last reported at -$10.7 million in Q1 2026.
- Quarterly Free Cash Flow fell 51.38% year-over-year to -$10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.1 million (up 0.59% YoY) and the FY2025 annual result came in at -$20.5 million, up 17.52% from the prior year.
- Free Cash Flow eased to -$10.7 million in Q1 2026, from -$3.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$3.6 million in Q3 2025 to a low of -$12.0 million in Q2 2022.
- A 5-year average of -$7.5 million and a median of -$7.1 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 112.8% — and 2024, when it soared 37.83%.
- Tracing FTH's Free Cash Flow over 5 years: stood at -$9.6 million in 2022, then soared by 35.63% to -$6.2 million in 2023, then climbed by 6.02% to -$5.8 million in 2024, then jumped by 33.29% to -$3.9 million in 2025, then tumbled by 177.92% to -$10.7 million in 2026.
- The last three Free Cash Flow figures came in at -$10.7 million (Q1 2026), -$3.9 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 477.44 Mn |
| 10 | Faeth Therapeutics | 176.58 Mn | 176.58 Mn | - | -15.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.67 Mn |
| Jun 30, 2026 | -15.67 Mn |
| Mar 31, 2026 | -10.74 Mn |
| Mar 31, 2026 | -10.74 Mn |
| Dec 31, 2025 | -3.86 Mn |
| Dec 31, 2025 | -3.86 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Jun 30, 2025 | -5.93 Mn |
| Jun 30, 2025 | -5.93 Mn |
| Mar 31, 2025 | -7.09 Mn |
| Mar 31, 2025 | -7.09 Mn |
| Dec 31, 2024 | -5.79 Mn |
| Dec 31, 2024 | -5.79 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Jun 30, 2024 | -5.90 Mn |
| Jun 30, 2024 | -5.90 Mn |
| Mar 31, 2024 | -7.65 Mn |
| Mar 31, 2024 | -7.65 Mn |